Published: 20 April 2015
Author(s): Giulio Formoso, Nicola Magrini, Anna Maria Marata
Section: Letters to the Editor

Pharmaceutical policies favoring appropriate prescribing must be based on solid evidence on drug effectiveness and safety, better if shared with relevant stakeholders [1]. To translate this knowledge into practice further steps are generally needed, like setting specific indicators and goals [2] and associating economic incentives [3]. In keeping with these general principles, in 2011 Health Authorities of Emilia-Romagna (ER), a Region in Northern Italy, appointed a multidisciplinary panel to review and discuss evidence on inhibitors of the renin–angiotensin system (ACE inhibitors and sartans), widely used drugs with similar indications in cardiovascular medicine, nephrology and diabetes.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.